Latest News
Adial Pharmaceuticals, Inc.
- People on the Move: David Rubenstein Named Chief Scientist at Adial Pharmaceuticals
- Adial Pharmaceuticals adjourns votes on Nasdaq-dependent proposals, reconvenes meeting Oct. 26
- Adial Pharmaceuticals appoints David Rubenstein as chief scientist
- Adial Pharmaceuticals Appoints David Rubenstein as Chief Scientist
- Adial Pharmaceuticals appoints David Rubenstein as chief scientist
- Adial Pharmaceuticals Appoints AhR Drug Development Veteran David Rubenstein as Chief Scientist to Advance AT177 for Ulcerative Colitis
- The scientist who led development of an FDA-approved skin treatment will guide Adial's ulcerative colitis drug.
- Adial Pharmaceuticals appoints David Rubenstein as Chief Scientist to advance ulcerative colitis drug AT177.
- Adial Pharmaceuticals adjourns votes pending Nasdaq listing approval, reconvenes Oct 15
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- $Adial Pharmaceuticals (ADIL.US)$ Bear flag with bounce off support
Headlines from the last 30 days, linking to the original publishers. See all market news →